SCHEMBL16057363

SCHEMBL16057363

O=C(O)n1cccc(CCOCCC2CCCCC2)c1=O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 6/20 0.36
▸ CHRM4 P08173 6/20 0.36
▸ CHRM5 P08912 6/20 0.36
▸ CHRM1 P11229 6/20 0.36
▸ CHRM3 P20309 6/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ CYSLTR2 Q9NS75 1/20 0.36
▸ CYSLTR1 Q9Y271 1/20 0.36
▸ KMT2A Q03164 1/20 0.35
▸ PPARG P37231 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NAAA Q02083 2/20 0.33
▸ ASAH1 Q13510 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ CEL P19835 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16057274 0.89 SPHK1 (0.39) NAAA
SCHEMBL16057072 0.85 CYSLTR2 (0.46) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL16057607 0.84 CYSLTR2 (0.50) KDM4ECYSLTR2CYSLTR1KMT2ANAAA
SCHEMBL14975358 0.84 CYSLTR2 (0.50) KDM4ECYSLTR2CYSLTR1KMT2ANAAA
SCHEMBL16057735 0.84 CYSLTR2 (0.44) KDM4ECYSLTR2CYSLTR1KMT2APPARG
SCHEMBL16057719 0.83 CYSLTR2 (0.48) KDM4ECYSLTR2CYSLTR1KMT2ANAAA
SCHEMBL14975393 0.78 TDP1 (0.38) ALDH1A1TP53LMNA
SCHEMBL16058382 0.77 TERT (0.38) KDM4ECYSLTR2CYSLTR1ALDH1A1LMNA
SCHEMBL16058140 0.72 HAO1 (0.39) NAAAASAH1
SCHEMBL16057313 0.72 CYSLTR2 (0.39) CYSLTR2CYSLTR1KMT2ANAAACEL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9828338-B2 Carbamate derivatives of lactam based N-acylethanolamine acid amidase (NAAA) inhibitors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-11-28 — — US disclosed
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-03-10 — — US disclosed
WO-2014144836-A2 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068482-A1 CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS NAAA, FAAH, FAAH2 CHRM2 3320/4885CHRM4 3041/4885CHRM5 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback